Are clinical pharmacology studies still needed in childhood acute lymphoblastic leukemia?
作者信息
Conter Valentino, Ceppi Francesco
机构信息
Pediatric Hemato-Oncology, Fondazione MBBM, University Milano Bicocca, Ospedale San Gerardo, Monza, Italy.
Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department Woman-Mother-Child, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
出版信息
Haematologica. 2022 Feb 1;107(2):356-357. doi: 10.3324/haematol.2021.279059.
Abstract
摘要
相似文献
1
Are clinical pharmacology studies still needed in childhood acute lymphoblastic leukemia?
Haematologica. 2022 Feb 1;107(2):356-357. doi: 10.3324/haematol.2021.279059.
2
[Childhood acute lymphoblastic leukemia (ALL)].
Rinsho Ketsueki. 2013 Jan;54(1):100-8.
3
Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials.
Recent Results Cancer Res. 1993;131:123-32. doi: 10.1007/978-3-642-84895-7_12.
4
The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005.
Leukemia. 2005 Jul;19(7):1145-52. doi: 10.1038/sj.leu.2403783.
5
[Childhood acute lymphoblastic leukemia; pathophysiology and treatment strategy].
Rinsho Ketsueki. 2013 Nov;54(11):2038-46.
6
International Childhood Acute Lymphoblastic Leukemia Workshop: Sausalito, CA, 30 November-1 December 2000.
Leukemia. 2001 May;15(5):707-15. doi: 10.1038/sj.leu.2402111.
7
Pharmacogenetics of childhood acute lymphoblastic leukemia.
Pharmacogenomics. 2014 Jul;15(10):1383-98. doi: 10.2217/pgs.14.106.
8
Pharmacology and drug resistance in childhood lymphoblastic leukemia.
Hematol Oncol Clin North Am. 1990 Oct;4(5):871-94.
9
Pharmacogenetics of acute lymphoblastic leukemia treatment response.
Expert Opin Pharmacother. 2007 Oct;8(15):2519-31. doi: 10.1517/14656566.8.15.2519.
10
CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
Haematologica. 2017 Apr;102(4):736-745. doi: 10.3324/haematol.2016.145177. Epub 2016 Dec 15.
本文引用的文献
1
Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy.
Haematologica. 2022 Feb 1;107(2):371-380. doi: 10.3324/haematol.2021.278411.
2
Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.
Cancer. 2018 Mar 15;124(6):1150-1159. doi: 10.1002/cncr.31099. Epub 2017 Dec 19.
3
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
Leukemia. 2018 Mar;32(3):606-615. doi: 10.1038/leu.2017.265. Epub 2017 Aug 18.
4
Prolonged standard native asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27.
5
6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.
Blood. 2014 Oct 9;124(15):2345-53. doi: 10.1182/blood-2014-01-552166. Epub 2014 May 14.
6
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
J Clin Oncol. 2001 Mar 1;19(5):1297-303. doi: 10.1200/JCO.2001.19.5.1297.
7
8
Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
J Clin Oncol. 1997 Jun;15(6):2222-30. doi: 10.1200/JCO.1997.15.6.2222.
9
More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials.
Haematol Blood Transfus. 1990;33:459-66. doi: 10.1007/978-3-642-74643-7_83.
10
Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols.
Ann Oncol. 1991 Nov-Dec;2(10):745-9. doi: 10.1093/oxfordjournals.annonc.a057856.
Zotero 插件